Additional Information

Description

Avsola™ Biosimilar Of Remicade® Infliximab-Axxq 100 Mg Injection Single-Dose Vial is a biosimilar formulation of infliximab, designed for the treatment of autoimmune disorders. It is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-a), a key cytokine involved in inflammatory responses. By inhibiting TNF-a, the drug helps reduce inflammation, tissue damage, and disease progression in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

The medication is supplied as a preservative-free, lyophilized powder for intravenous infusion. Before administration, the powder must be reconstituted and diluted in sterile conditions. Infusions are typically given at regular intervals based on patient response and disease severity. To minimize infusion-related reactions, premedication with antihistamines, acetaminophen, or corticosteroids may be required. 

Common side effects include headache, nausea, fatigue, upper respiratory infections, and infusion reactions. Serious adverse effects may include severe infections, tuberculosis reactivation, malignancies, hepatotoxicity, and hypersensitivity reactions. Patients should undergo screening for infections and tuberculosis before treatment initiation, and regular monitoring is recommended.